Evidence map›Paper›PMID 32454759›Full record

ArticleTurkish journal of pharmaceutical sciences2020

Meryem Sedef Erdal, Aslı Gürbüz, Seher Birteksöz Tan, Sevgi Güngör, Yıldız Özsoy

Abstract read
In one paragraph

Article in Turkish journal of pharmaceutical sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Meryem Sedef Erdalİstanbul University, Faculty of Pharmacy, Department of Pharmaceutical Technology, İstanbul, Turkey.ORCID https://orcid.org/0000-0001-6220-2036
Aslı Gürbüzİstanbul University, Faculty of Pharmacy, Department of Pharmaceutical Technology, İstanbul, Turkey.ORCID https://orcid.org/0000-0002-1389-1581
Seher Birteksöz Tanİstanbul University, Faculty of Pharmacy, Department of Pharmaceutical Microbiology, İstanbul, Turkey.ORCID https://orcid.org/0000-0003-2123-1468
Sevgi Güngörİstanbul University, Faculty of Pharmacy, Department of Pharmaceutical Technology, İstanbul, Turkey.ORCID https://orcid.org/0000-0002-8199-3010
Yıldız Özsoyİstanbul University, Faculty of Pharmacy, Department of Pharmaceutical Technology, İstanbul, Turkey.ORCID https://orcid.org/0000-0002-9110-3704

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesMicroemulsions are fluid, isotropic, colloidal systems that have been widely studied as drug delivery systems. The percutaneous transport of active agents can be enhanced by their microemulsion formulation when compared to conventional formulations. The purpose of this study was to evaluate naftifine-loaded microemulsions with the objective of improving the skin permeation of the drug. MATERIALS AND

methodsMicroemulsions comprising oleic acid (oil phase), Kolliphor EL or Kolliphor RH40 (surfactant), Transcutol (co-surfactant), and water were prepared and physicochemical characterization was performed.

resultsThe microemulsion formulation containing Kolliphor RH40 as co-surfactant increased naftifine permeation through pig skin significantly when compared with the commercial topical formulation (p<0.05). ATR-FTIR spectroscopy showed that microemulsions increased the fluidity of the stratum corneum lipid bilayers. Drug-loaded microemulsions possessed superior antifungal activity against

conclusionThis study demonstrated that microemulsions could be suggested as an alternative topical carrier with potential for enhanced skin delivery of naftifine.

Indexed as

colloidal drug carrier systemmicroemulsionNaftifinetopical antifungal

Identifiers

PMID32454759
PMCPMC7227865

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.